"Brief Introduction of China Food & Drug Administration" by Chang Yongheng, China Centre for Food and Drug International Exchange, China Food & Drug Administration
MedWatch is the FDA's program for monitoring the safety of medical products. It allows voluntary reporting of adverse events by the public and healthcare professionals. Reports are collected in a database and monitored by FDA professionals. The FDA uses these reports to identify safety issues, communicate new safety information to the public and healthcare providers, and take regulatory actions like requiring label changes or product recalls when needed. The goal is to help protect public health by ensuring the safety of drugs, medical devices and other medical products.
The document discusses post-approval changes that can be made to approved NDAs and ANDAs. It describes four reporting categories for post-approval changes based on their potential impact: major changes requiring prior approval, moderate changes reported via a CBE-30 or CBE-0 supplement, minor changes reported annually. Examples are provided for different types of changes that fall under each reporting category. The levels of reporting ensure that manufacturers can make certain changes while providing appropriate notification to the FDA depending on the level of change.
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESVikas Rathee
The document discusses regulatory requirements for drug registration in Asian countries. It provides an overview of the ASEAN Common Technical Dossier (ACTD) format for drug applications across ASEAN countries. It then summarizes requirements for registration in China, South Korea, and with the ASEAN region. For China, it outlines the drug classification system and two-step approval process. For South Korea, it describes the drug classification and approval process including investigational new drug applications. It also provides background on the goals and formation of the ASEAN economic alliance between Southeast Asian countries.
GVP stands for Good Pharmacovigilance Practices, which are a set of guidelines and regulatory requirements that provide a framework for the conduct of pharmacovigilance activities. The GVP modules outline specific areas of pharmacovigilance and provide detailed guidance on various aspects. Here are the main GVP modules
NSF certification, Standard for dietary supplementAtul Bhombe
NSF International is an independent organization that develops standards and certification programs to protect public health. They provide third-party certification to verify that products meet technical standards. NSF has developed Standard 173 for dietary supplements, which includes testing for contaminants and verifying label claims. The standard outlines requirements for raw materials, finished products, and labeling of dietary supplements. Manufacturers must submit information about product composition and testing methods to verify label claims under the standard.
This document provides a checklist of documents required for obtaining market authorization in various BRICS countries. It introduces BRICS as an emerging market comprising Brazil, Russia, India, China and South Africa. Reasons for the emergence of BRICS markets include declining growth in developed markets and availability of patient populations in emerging markets. The checklist then outlines the documents required for market authorization from the regulatory authorities in India, China, South Africa and other BRICS countries. These include application forms, composition details, clinical trial reports, GMP certificates, and other product-specific documents.
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
This document outlines the regulatory requirements and approval procedures for drugs, cosmetics, medical devices, biological products, herbal medicines, and foods/nutraceuticals in India. It discusses the key regulatory bodies like the Central Drugs Standard Control Organization (CDSCO) and the application processes. For drugs, the new drug approval procedure is described involving applying to the DCGI and undergoing clinical trials and reviews. For other products, the document explains the application forms and documents required for approval from bodies like FSSAI.
MedWatch is the FDA's program for monitoring the safety of medical products. It allows voluntary reporting of adverse events by the public and healthcare professionals. Reports are collected in a database and monitored by FDA professionals. The FDA uses these reports to identify safety issues, communicate new safety information to the public and healthcare providers, and take regulatory actions like requiring label changes or product recalls when needed. The goal is to help protect public health by ensuring the safety of drugs, medical devices and other medical products.
The document discusses post-approval changes that can be made to approved NDAs and ANDAs. It describes four reporting categories for post-approval changes based on their potential impact: major changes requiring prior approval, moderate changes reported via a CBE-30 or CBE-0 supplement, minor changes reported annually. Examples are provided for different types of changes that fall under each reporting category. The levels of reporting ensure that manufacturers can make certain changes while providing appropriate notification to the FDA depending on the level of change.
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESVikas Rathee
The document discusses regulatory requirements for drug registration in Asian countries. It provides an overview of the ASEAN Common Technical Dossier (ACTD) format for drug applications across ASEAN countries. It then summarizes requirements for registration in China, South Korea, and with the ASEAN region. For China, it outlines the drug classification system and two-step approval process. For South Korea, it describes the drug classification and approval process including investigational new drug applications. It also provides background on the goals and formation of the ASEAN economic alliance between Southeast Asian countries.
GVP stands for Good Pharmacovigilance Practices, which are a set of guidelines and regulatory requirements that provide a framework for the conduct of pharmacovigilance activities. The GVP modules outline specific areas of pharmacovigilance and provide detailed guidance on various aspects. Here are the main GVP modules
NSF certification, Standard for dietary supplementAtul Bhombe
NSF International is an independent organization that develops standards and certification programs to protect public health. They provide third-party certification to verify that products meet technical standards. NSF has developed Standard 173 for dietary supplements, which includes testing for contaminants and verifying label claims. The standard outlines requirements for raw materials, finished products, and labeling of dietary supplements. Manufacturers must submit information about product composition and testing methods to verify label claims under the standard.
This document provides a checklist of documents required for obtaining market authorization in various BRICS countries. It introduces BRICS as an emerging market comprising Brazil, Russia, India, China and South Africa. Reasons for the emergence of BRICS markets include declining growth in developed markets and availability of patient populations in emerging markets. The checklist then outlines the documents required for market authorization from the regulatory authorities in India, China, South Africa and other BRICS countries. These include application forms, composition details, clinical trial reports, GMP certificates, and other product-specific documents.
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
This document outlines the regulatory requirements and approval procedures for drugs, cosmetics, medical devices, biological products, herbal medicines, and foods/nutraceuticals in India. It discusses the key regulatory bodies like the Central Drugs Standard Control Organization (CDSCO) and the application processes. For drugs, the new drug approval procedure is described involving applying to the DCGI and undergoing clinical trials and reviews. For other products, the document explains the application forms and documents required for approval from bodies like FSSAI.
The document discusses drug registration processes and formats used in ASEAN countries. It provides information on the individual drug registration systems of each ASEAN member state, which countries have their own formats versus following the common ASEAN CTD format. Export of Indian AYUSH products to ASEAN countries has increased significantly between 2004-2008. The common ASEAN CTD format is described in detail with its section headings.
This standard provides requirements for testing dietary supplements to ensure ingredients are accurately identified and labeled. It requires supplements to be tested to confirm identity, quantity, and limits on contaminants like metals, pesticides, and microbes. The standard also provides criteria for good manufacturing practices. It applies to supplements containing vitamins, minerals, herbs, amino acids, or other botanical ingredients but excludes conventional foods.
This document summarizes the objectives and classification system of the Global Harmonization Task Force (GHTF) for in vitro diagnostic (IVD) medical devices. The GHTF was founded in 1993 to harmonize medical device regulations globally. It aims to facilitate trade while preserving public health. IVD medical devices are classified into 4 risk-based classes (A to D) based on 16 general rules related to device invasiveness, energy use, and disease detection. Class A devices pose the lowest risk while Class D the highest. The classification system aims to ensure regulatory oversight is proportionate to device risk.
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxSanthiNori1
1) The Global Medical Device Nomenclature (GMDN) is an internationally agreed system that provides a single common language of generic terms to uniquely identify medical devices. It aims to be adopted by medical device regulators, manufacturers and healthcare systems worldwide.
2) GMDN terms consist of a name, definition and code. Terms are searched on the GMDN agency website and used for data exchange between organizations. A unique device identifier (UDI) also uses GMDN codes.
3) GMDN was established in 1991 to allow efficient information exchange between stakeholders. It is important for regulatory approval and identification of product failures or inventory management.
This document provides information on drug master files (DMFs), including:
- There are 5 types of DMFs which contain information on drug substances, packaging materials, excipients, and other reference materials.
- A Type II DMF contains information about drug substances and products, and must be submitted in ICH CTD format.
- Modules 1-3 of the CTD are included in a DMF, with Module 1 containing administrative information, Module 2 providing a quality overall summary, and Module 3 containing detailed information on manufacturing, characterization, and controls.
- DMF holders must notify authorized parties of any amendments and provide annual reports on the anniversary of the original submission.
medical device regulatory approval in USASuraj Pamadi
The document discusses the approval process for medical devices in the United States, including an overview of the classification system for medical devices (Class I, II, III), the requirements for each class (e.g. 510(k) notification or premarket approval), and the components required for a 510(k) premarket notification application to the FDA.
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
This presentation contain detailed information about the "Regulation Governing Clinical Trials In India,USA and Europe".And about the clinical trails and medical devices regulations in India.
The document provides guidance for regulatory audits of medical device manufacturers' quality management systems. It discusses the Global Harmonization Task Force (GHTF), which aimed to harmonize medical device regulations internationally. GHTF established 5 study groups, including Study Group 4 which focused on auditing strategies and developed guidance documents. The guidance covers establishing auditing procedures, auditor competencies, and conducting and documenting audits in a harmonized manner. It provides a framework for consistent regulatory audits of medical device quality systems across countries.
The document discusses clinical trial regulation in the European Union. It provides information on two key directives - Directive 2001/20/EC which describes requirements for conducting clinical trials in the EU, and Commission Directive 2005/28/EC which implements principles of good clinical practice. It then summarizes Regulation 536/2014 adopted in 2014 which established a new regulation for clinical trials of medicinal products in the EU with the aim of increasing patient safety, reliability of data, and efficiency of trials. The regulation includes provisions for single submission of documentation, centralized assessment, transparency, informed consent, and safety reporting among others.
1. The PMDA (Pharmaceuticals and Medical Devices Agency) is the Japanese regulatory agency that reviews submissions for drug and medical device approval to ensure safety, efficacy, and quality. It was established in 2004.
2. To market a drug in Japan, approval must be obtained for each product by demonstrating efficacy and safety through examinations. Foreign manufacturers must be accredited through the FMA process. Medical devices are classified and require pre-market notification, certification, or approval depending on the risk class.
3. Registering products in Japan requires navigating a complex process that can involve clinical trials and high fees. Pursuing product registration requires carefully considering the market demand to determine if pursuing approval is worthwhile.
The document summarizes changes to ISO 14155:2020 for clinical investigations involving medical devices. It notes that the standard now explicitly includes post-market investigations and software devices. Key changes include expanded risk-based monitoring allowing on-site or centralized approaches, new event escalation procedures, and emphasis on risk management throughout the clinical trial process. While GCP principles are becoming more aligned between ISO 14155 and ICH-GCP, some differences remain in adverse event reporting and how product risks and training are addressed.
This document outlines quality system requirements for national pharmaceutical inspection services that conduct GMP inspections of manufacturers and wholesale distributors. It specifies that inspection services must establish a quality manual, administrative structure, documentation control, records management, inspection procedures and resources, internal audits, quality improvement processes, and procedures for handling complaints and recalls. The goal is to achieve consistency in inspection standards across national authorities to facilitate mutual recognition and confidence between inspection services.
This document discusses various post-approval requirements and processes for pharmaceutical drugs, including prior approval supplements, changes being effected in 30 days supplements, annual reports, labeling changes, recalls, FDA inspections, and ISO 31000 risk management standards. It provides details on submission requirements and timelines for different types of post-approval changes, as well as FDA enforcement actions like warning letters, seizures, and injunctions.
Financial Disclosure –Duties and Strategies for Clinical StudiesMichael Swit
Financial disclosure requirements for clinical studies are explored with a particular emphasis on how the requirement for tracking "Significant Payments of Other Sorts" -- or SPOOS -- present challenges in clinical study compliance.
International Medical Device Regulators ForumSanthiNori1
The document summarizes the International Medical Device Regulators Forum (IMDRF), which was established in 2011 to accelerate international harmonization of medical device regulations. It provides background on IMDRF's establishment and membership, which includes regulators from 11 countries and regions. The document also discusses IMDRF's relationship to the prior Global Harmonization Task Force (GHTF) and describes IMDRF's management structure, meetings, and current working groups on issues like adverse event terminology and medical device cybersecurity.
The European Medicines Agency (EMA) regulates medicines for both human and veterinary use across Europe. Key responsibilities of EMA include evaluating applications for new medicines and monitoring approved medicines. EMA operates through various scientific committees and follows regulatory procedures for clinical trials and marketing authorization applications. EMA helps ensure that medicines available across Europe are safe, effective and of high quality.
This document discusses various FDA approval pathways for drugs, biologics, and medical devices. It describes the New Drug Application (NDA) process for drug approval, the Biologics License Application (BLA) process for biologics approval, the Premarket Approval (PMA) process for high-risk Class III medical devices, and the 510(k) process for clearance of lower-risk Class I and II medical devices. The key FDA regulations and goals of demonstrating safety and effectiveness for intended uses are also summarized.
Informa - Demonstrating Your PARP Inhibitor's ValueDan Ngo
The document discusses making a business case for a PARP inhibitor drug in the ovarian cancer market. It provides information from various data sources on competitor drugs and clinical trials, the size of the ovarian cancer market, sales forecasts for Lynparza and other PARP inhibitors, and deal values that phase 1 oncology drugs and PARP inhibitors have achieved when licensed.
PARP-1 inhibitors have shown promise in oncology by potentiating the effects of DNA damaging chemotherapy agents. Cephalon identified a pyrrolocarbazole hit that inhibited PARP-1 but had poor properties. Through structure-based design and SAR studies, they developed CEP-8983, a potent PARP inhibitor. A prodrug, CEP-9722, was synthesized to improve solubility and pharmacokinetics. In preclinical studies, CEP-8983 and its active metabolite CEP-9397 potentiated the effects of temozolomide in tumor cell lines. CEP-9722 advanced to Phase 1 and 2 clinical trials for evaluation as monotherapy and
The document discusses drug registration processes and formats used in ASEAN countries. It provides information on the individual drug registration systems of each ASEAN member state, which countries have their own formats versus following the common ASEAN CTD format. Export of Indian AYUSH products to ASEAN countries has increased significantly between 2004-2008. The common ASEAN CTD format is described in detail with its section headings.
This standard provides requirements for testing dietary supplements to ensure ingredients are accurately identified and labeled. It requires supplements to be tested to confirm identity, quantity, and limits on contaminants like metals, pesticides, and microbes. The standard also provides criteria for good manufacturing practices. It applies to supplements containing vitamins, minerals, herbs, amino acids, or other botanical ingredients but excludes conventional foods.
This document summarizes the objectives and classification system of the Global Harmonization Task Force (GHTF) for in vitro diagnostic (IVD) medical devices. The GHTF was founded in 1993 to harmonize medical device regulations globally. It aims to facilitate trade while preserving public health. IVD medical devices are classified into 4 risk-based classes (A to D) based on 16 general rules related to device invasiveness, energy use, and disease detection. Class A devices pose the lowest risk while Class D the highest. The classification system aims to ensure regulatory oversight is proportionate to device risk.
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxSanthiNori1
1) The Global Medical Device Nomenclature (GMDN) is an internationally agreed system that provides a single common language of generic terms to uniquely identify medical devices. It aims to be adopted by medical device regulators, manufacturers and healthcare systems worldwide.
2) GMDN terms consist of a name, definition and code. Terms are searched on the GMDN agency website and used for data exchange between organizations. A unique device identifier (UDI) also uses GMDN codes.
3) GMDN was established in 1991 to allow efficient information exchange between stakeholders. It is important for regulatory approval and identification of product failures or inventory management.
This document provides information on drug master files (DMFs), including:
- There are 5 types of DMFs which contain information on drug substances, packaging materials, excipients, and other reference materials.
- A Type II DMF contains information about drug substances and products, and must be submitted in ICH CTD format.
- Modules 1-3 of the CTD are included in a DMF, with Module 1 containing administrative information, Module 2 providing a quality overall summary, and Module 3 containing detailed information on manufacturing, characterization, and controls.
- DMF holders must notify authorized parties of any amendments and provide annual reports on the anniversary of the original submission.
medical device regulatory approval in USASuraj Pamadi
The document discusses the approval process for medical devices in the United States, including an overview of the classification system for medical devices (Class I, II, III), the requirements for each class (e.g. 510(k) notification or premarket approval), and the components required for a 510(k) premarket notification application to the FDA.
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
This presentation contain detailed information about the "Regulation Governing Clinical Trials In India,USA and Europe".And about the clinical trails and medical devices regulations in India.
The document provides guidance for regulatory audits of medical device manufacturers' quality management systems. It discusses the Global Harmonization Task Force (GHTF), which aimed to harmonize medical device regulations internationally. GHTF established 5 study groups, including Study Group 4 which focused on auditing strategies and developed guidance documents. The guidance covers establishing auditing procedures, auditor competencies, and conducting and documenting audits in a harmonized manner. It provides a framework for consistent regulatory audits of medical device quality systems across countries.
The document discusses clinical trial regulation in the European Union. It provides information on two key directives - Directive 2001/20/EC which describes requirements for conducting clinical trials in the EU, and Commission Directive 2005/28/EC which implements principles of good clinical practice. It then summarizes Regulation 536/2014 adopted in 2014 which established a new regulation for clinical trials of medicinal products in the EU with the aim of increasing patient safety, reliability of data, and efficiency of trials. The regulation includes provisions for single submission of documentation, centralized assessment, transparency, informed consent, and safety reporting among others.
1. The PMDA (Pharmaceuticals and Medical Devices Agency) is the Japanese regulatory agency that reviews submissions for drug and medical device approval to ensure safety, efficacy, and quality. It was established in 2004.
2. To market a drug in Japan, approval must be obtained for each product by demonstrating efficacy and safety through examinations. Foreign manufacturers must be accredited through the FMA process. Medical devices are classified and require pre-market notification, certification, or approval depending on the risk class.
3. Registering products in Japan requires navigating a complex process that can involve clinical trials and high fees. Pursuing product registration requires carefully considering the market demand to determine if pursuing approval is worthwhile.
The document summarizes changes to ISO 14155:2020 for clinical investigations involving medical devices. It notes that the standard now explicitly includes post-market investigations and software devices. Key changes include expanded risk-based monitoring allowing on-site or centralized approaches, new event escalation procedures, and emphasis on risk management throughout the clinical trial process. While GCP principles are becoming more aligned between ISO 14155 and ICH-GCP, some differences remain in adverse event reporting and how product risks and training are addressed.
This document outlines quality system requirements for national pharmaceutical inspection services that conduct GMP inspections of manufacturers and wholesale distributors. It specifies that inspection services must establish a quality manual, administrative structure, documentation control, records management, inspection procedures and resources, internal audits, quality improvement processes, and procedures for handling complaints and recalls. The goal is to achieve consistency in inspection standards across national authorities to facilitate mutual recognition and confidence between inspection services.
This document discusses various post-approval requirements and processes for pharmaceutical drugs, including prior approval supplements, changes being effected in 30 days supplements, annual reports, labeling changes, recalls, FDA inspections, and ISO 31000 risk management standards. It provides details on submission requirements and timelines for different types of post-approval changes, as well as FDA enforcement actions like warning letters, seizures, and injunctions.
Financial Disclosure –Duties and Strategies for Clinical StudiesMichael Swit
Financial disclosure requirements for clinical studies are explored with a particular emphasis on how the requirement for tracking "Significant Payments of Other Sorts" -- or SPOOS -- present challenges in clinical study compliance.
International Medical Device Regulators ForumSanthiNori1
The document summarizes the International Medical Device Regulators Forum (IMDRF), which was established in 2011 to accelerate international harmonization of medical device regulations. It provides background on IMDRF's establishment and membership, which includes regulators from 11 countries and regions. The document also discusses IMDRF's relationship to the prior Global Harmonization Task Force (GHTF) and describes IMDRF's management structure, meetings, and current working groups on issues like adverse event terminology and medical device cybersecurity.
The European Medicines Agency (EMA) regulates medicines for both human and veterinary use across Europe. Key responsibilities of EMA include evaluating applications for new medicines and monitoring approved medicines. EMA operates through various scientific committees and follows regulatory procedures for clinical trials and marketing authorization applications. EMA helps ensure that medicines available across Europe are safe, effective and of high quality.
This document discusses various FDA approval pathways for drugs, biologics, and medical devices. It describes the New Drug Application (NDA) process for drug approval, the Biologics License Application (BLA) process for biologics approval, the Premarket Approval (PMA) process for high-risk Class III medical devices, and the 510(k) process for clearance of lower-risk Class I and II medical devices. The key FDA regulations and goals of demonstrating safety and effectiveness for intended uses are also summarized.
Informa - Demonstrating Your PARP Inhibitor's ValueDan Ngo
The document discusses making a business case for a PARP inhibitor drug in the ovarian cancer market. It provides information from various data sources on competitor drugs and clinical trials, the size of the ovarian cancer market, sales forecasts for Lynparza and other PARP inhibitors, and deal values that phase 1 oncology drugs and PARP inhibitors have achieved when licensed.
PARP-1 inhibitors have shown promise in oncology by potentiating the effects of DNA damaging chemotherapy agents. Cephalon identified a pyrrolocarbazole hit that inhibited PARP-1 but had poor properties. Through structure-based design and SAR studies, they developed CEP-8983, a potent PARP inhibitor. A prodrug, CEP-9722, was synthesized to improve solubility and pharmacokinetics. In preclinical studies, CEP-8983 and its active metabolite CEP-9397 potentiated the effects of temozolomide in tumor cell lines. CEP-9722 advanced to Phase 1 and 2 clinical trials for evaluation as monotherapy and
This document summarizes the key aspects of the Chinese pharmaceutical market. It discusses the size and growth prospects of the market, driven by factors like rising incomes, healthcare spending, and an aging population. It outlines the regulatory approval process and describes segments of the market like generics, patented drugs, and biologics. The market is large and complex but offers opportunities for companies that can navigate the regulatory system and target specific segments.
1. Corifollitropin alfa is a recombinant gonadotropin that provides a single dose alternative to multiple daily injections of recombinant FSH for controlled ovarian stimulation.
2. Clinical trials have found corifollitropin alfa to be as effective as daily recombinant FSH with similar outcomes for number of oocytes retrieved, ongoing pregnancy rates, and live birth rates.
3. Safety profiles were also similar between corifollitropin alfa and daily recombinant FSH with no evidence of immunogenicity found.
An Introduction of Healthcare Market in ChinaZiqian WANG
A research on healthcare market in China covering topics including an introduction of Public Hospital System, Chinese Physicians' Work Condition and Salaries, as well as Continued Medical Education system.
Regulatory Highlights and Drug Development in ChinaMedpace
Regulatory Highlights and Drug Development in China was presented at the 5th China Clinical Trials Outsourcing Congress March 4-5, 2013 by Xiaoxiong (Jim) Wei, MD, PhD, Medical Director at Medpace.
Elonva: A new patient friendly approach in ARTYuzko Olexandr
1. A new drug called Elonva (corifollitropin alfa) provides a patient-friendly approach to ovarian stimulation in ART by reducing the complexity and burden of treatment through shorter stimulation cycles and fewer injections compared to traditional gonadotropins.
2. Studies show Elonva individualizes treatment by optimizing ovarian response and risk of OHSS while maintaining or increasing pregnancy rates.
3. Starting gonadotropin stimulation on cycle day 4 reduces the total dose and duration of stimulation compared to day 2 with no difference in outcomes.
Chinese Food and Drug Administration (CFDA) Regulatory Approval Process: Medi...NAMSA
The document summarizes China's regulatory approval process for medical devices. It outlines the testing process manufacturers must go through, including writing custom product standards and undergoing variable performance testing at CFDA-designated sites. Recent changes require Class I devices to file documentation rather than register, and Class II and III devices to conduct clinical trials for approval, with some exceptions. IVD registration requirements also changed, with Class I through filing, and Classes II and III requiring registration and trials.
Regulatory control of pharmaceuticals aims to ensure drug safety, efficacy and quality. Key aspects of regulation include drug evaluation and licensing, manufacturing standards, import/export controls, and adverse event monitoring. The main regulatory bodies in India are the Central Drugs Standard Control Organization, which oversees drug approvals, good manufacturing practices and quality control, and the Drugs Controller General of India. Indian drug laws and policies are guided by organizations like the Indian Pharmacopoeia Commission, which establishes drug standards.
The document summarizes the evolution and current status of the Pharmacovigilance Programme of India (PvPI). It describes how PvPI has grown from its launch by the Ministry of Health & Family Welfare to now include 210 adverse drug reaction monitoring centers across the country. PvPI has strengthened pharmacovigilance in India by integrating national health programs, establishing legal obligations for drug manufacturers, and increasing annual adverse drug reaction reports from 14,685 in 2011 to over 225,000 currently. PvPI has also gained recognition internationally by contributing to WHO publications and receiving top benchmark ratings from WHO for its national regulatory authority system.
This document is the 2014 annual report of the Taiwan Food and Drug Administration (TFDA). It discusses the TFDA's organizational structure, administrative objectives, policies and regulations for managing food, medicinal products, medical devices and cosmetics. Key highlights include strengthening food safety laws, shortening drug review timelines, expanding medical device sales channels, increasing border inspections, and enhancing international cooperation. The TFDA aims to safeguard public health through a five-pronged strategy of ensuring a stable management system, controlling product imports and manufacturing, overseeing distribution, and protecting consumers.
This document discusses regulatory aspects of pharmaceuticals and bulk drug manufacturing. It provides an overview of key regulatory bodies in India that are responsible for drug regulation, including the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Indian Council of Medical Research, Indian Pharmacopoeia Commission, and National Pharmaceutical Pricing Authority. It also discusses Good Manufacturing Practices (GMP) guidelines and compliance, as well as regulatory frameworks from organizations like the World Health Organization and US Food and Drug Administration. The goal of drug regulation is to ensure safety, efficacy and quality of pharmaceutical products.
The document discusses clinical trials and drug regulation in India. It notes that India has become a preferred location for global clinical trials due to lower costs and a large pool of patients. However, this has also led to some cases of inadequate informed consent and unethical treatment. The document then summarizes key milestones in India's drug regulations from 1927 to the present, including establishment of regulatory bodies, amendments to better protect citizens and attract industry while ensuring high quality data. It also discusses the various ministries and guidelines involved in clinical trials and drug regulation in India.
The Center for Drug Evaluation and Research (CDER) is responsible for regulating prescription and over-the-counter drugs. CDER oversees new drug development and approval, drug safety, and drug advertising and promotion. It reviews New Drug Applications, monitors drug safety after approval, develops regulations and guidance, and communicates with industry and the public about drugs and drug development.
An Overview of CDSCO Registration. The CDSCO stands for Central Drugs Standard Control Organisation is the NRA or National Regulatory Authority under the Directorate General of Health Services, Government of India, and Ministry of Health and Family Welfare.
My presentation based on the CDSCO certification, as well as the complete description about the CDSCO and DCGI.
An Overview of CDSCO Registration. The CDSCO stands for Central Drugs Standard Control Organisation is the NRA or National Regulatory Authority under the Directorate General of Health Services, Government of India, and Ministry of Health and Family Welfare.
My presentation based on the CDSCO certification, as well as the complete description about the CDSCO and DCGI.
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for cosmetics, pharmaceuticals and medical devices. It functions under the Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. CDSCO regulates these industries through various departments, offices, and laboratories across India. It approves new drugs, clinical trials, imports, and medical devices. State drug control authorities also license and monitor quality in their respective states under CDSCO.
Pharma Uptoday Monthly Magazine Volume 7 issue Oct 2014Sathish Vemula
This document summarizes a report from Health Canada on drug GMP inspections conducted in fiscal year 2013-2014. Some key details include:
- 428 domestic drug GMP inspections were conducted and 411 received compliant ratings. 13 foreign inspections and 12 were compliant.
- The most frequently cited regulatory sections were for quality control, manufacturing control, and records requirements.
- Most observations (99%) were rated Risk 2 or 3 in terms of potential risk to patients.
- Key priorities for the program in 2014-2015 include enhancing risk management and collaborating with international partners.
The document discusses pharmacovigilance in India. It provides an overview of clinical trials in India, the history and programs of pharmacovigilance in the country, and current status of the Pharmacovigilance Program of India (PVPI). The PVPI aims to improve ADR reporting and monitoring across India through establishing ADR monitoring centers, but still faces challenges of underreporting and lack of nationwide awareness.
The document summarizes the WHO Prequalification Programme, which aims to ensure that medicines and health products meet global standards of quality, safety and efficacy. The key points are:
1. The programme comprehensively evaluates products based on manufacturer submissions and site inspections to verify compliance with WHO standards. Products that meet standards are added to the WHO prequalified lists.
2. The programme was launched in 2001 to address quality issues with medicines for HIV/AIDS, malaria, and tuberculosis in developing countries. It has since expanded to other health products and diseases.
3. The prequalification process involves an expression of interest, dossier submission and evaluation, site inspections, listing of prequalified products, ongoing monitoring, and de
This document provides an overview of industry and FDA liaison as well as ICH-Q guidelines. It discusses the roles and responsibilities of the FDA, including inspections, legal actions, and scientific review. It also describes the organization of the FDA and initiatives to expedite drug approval. Finally, it introduces ICH as an international harmonization effort and outlines the various ICH working groups and Q guidelines related to quality, safety, efficacy and other topics.
Fda gmp compliance for the Life Science Industrydmanalan
The document discusses good manufacturing practices (GMP) required by the FDA for life science companies. It provides an overview of GMP regulations for drugs, medical devices, and combination products. It explains that the FDA focuses on a "state of control" during inspections to assess compliance. While drug GMPs and device quality system regulations differ in some details, the overall systems are similar. The document reviews how the regulations address statistical techniques and quality systems. It also outlines the FDA's systems-based approach to inspections.
The document discusses pharmaceutical regulatory and healthcare laws in Pakistan. It outlines several key organizations that regulate the pharmaceutical industry, including the Drug Regulatory Authority of Pakistan (DRAP). It also summarizes various federal and provincial regulations related to drugs, healthcare facilities, and medical devices. Finally, it provides an overview of international pharmaceutical guidelines from organizations like the International Council for Harmonisation (ICH).
Horn of africa conference and expo, presentation on the regulatory framework for medical devices in kenya with the new guidelines requirement starting January 2019
The document discusses Kenya's efforts to strengthen regulation of medical devices and in vitro diagnostics (IVDs) to support universal health coverage. It outlines Kenya's regulatory system, including new guidelines for medical device registration and an online portal for submissions. A phased implementation approach is proposed, beginning with higher risk devices. International harmonization is emphasized to facilitate access while ensuring safety. The timeline targets public use of the online system and initial registrations in early 2019.
Medical devices are regulated under the Medical Device Rules published in 2017 and effective in 2018 in India. They include any instrument or material intended for human or animal use for diagnosis, treatment or prevention of disease. The Central Drugs Standard Control Organization regulates medical devices and some are notified under the Drugs and Cosmetics Act. There have been efforts to improve regulation of medical devices in India to focus on safety and appropriate use.
Similar to Brief Introduction to China FDA 2014 (20)
Here are the key principles to consider when planning meals:
- Meet nutrient recommendations by including a variety of foods in the correct serving sizes
- Consider individual factors like age, gender, health needs, culture and religion
- Plan meals within the available budget
- Alternate cooking methods like steaming, stir-frying and boiling
- Include seasonal fresh foods and consider the climate
- Prepare special dishes for occasions
This document discusses wine tourism as a centripetal force in the development of rural tourism. It defines wine tourism and explains its importance as a component of tourism in Croatia. Wine tourism can attract visitors to rural areas and support local economic development if integrated with other attractions of a destination in a sustainable way. The document outlines advantages and disadvantages of wine tourism for wine producers, consumers, and destinations. It concludes that wine has strong potential to draw tourists to destinations in Croatia if destinations are well-managed and wine tourism is developed while emphasizing its benefits and addressing challenges.
This presentation covers (1) Social impact of tourism; (2) Effects of globalization on tourism development; (3) Sex tourism and exploitation of women; and (4) Trends and issues shaping tourism and hospitality development.
Explore the Association for Vertical Farming infographics surrounding the topic of Urban and Vertical Farming. For more information, visit the Vertical Farming website: https://vertical-farming.net/
This document provides an overview of health food regulations in China. It discusses the key definitions and classifications of health foods, the major regulations governing health foods, and the processes for registration and filing of health foods. It also describes the document requirements, testing scopes, and differences between registration and filing. Registration involves more extensive dossier requirements, testing, and a longer timeline than filing. The document aims to help companies understand the regulatory landscape for placing health foods in the Chinese market.
This document provides information about food allergies and allergens. It lists common food allergens such as eggs, fish, milk, cereals containing gluten, and nuts. It then describes what a food allergy is versus a food intolerance, and lists potential symptoms of a food allergy such as hives, abdominal pain, and difficulty breathing. The document explains how to identify food allergens by checking food labels for bold, italicized listings of allergens. Lastly, it provides tips for managing a food allergy such as washing utensils, cleaning surfaces, informing restaurants of allergies, and being cautious of shared serving areas.
This document discusses food labelling regulations and challenges in ASEAN countries. It provides an overview of the general labelling requirements for Indonesia, Malaysia, Thailand and Singapore, which include the product name, ingredients list, net content, expiration date and manufacturer information. There are also country-specific details regarding language, format of dates and addresses, nutrition panel requirements. While general labelling information is similar, differences exist in details. Developing a common ASEAN food label is difficult due to mandatory country requirements, but harmonizing standards across ASEAN by referring to Codex guidelines could help address this challenge.
This document discusses considerations for developing a successful functional food product for the market. It begins by outlining upcoming trends in the industry, such as emerging economies and increasing health consciousness. Next, it identifies market drivers focused on consumers, like rising incomes and increasing awareness of health. Some key challenges in product development are ensuring healthy options are easy choices and delivering health, safety and quality. Five critical success factors for products are noticeability, superiority, compatibility, practicality and lack of complexity. The document provides a checklist for successful marketing that includes offering relevant benefits and differentiating through packaging. It emphasizes the importance of filtering promises from challenges in marketing.
This document discusses considerations for developing a successful functional food product. It notes consumers are shifting from illness management to wellness promotion. Functional foods fit within a continuum from health maintenance to promotion. Developing uniqueness through customization for intended populations and new research areas like nutrigenomics, proteomics and metabolomics can aid innovation. Biomarkers directly correlate health status to exposure. Encouraging development factors include epidemiological research, technological advancements, legislation and government incentives.
This document provides an overview of best practices for ensuring readiness for food safety audits and assessments. It begins with introductions and background on the speaker, Bill McBride. The agenda then outlines topics to be covered, including an overview of food safety audits, understanding common food safety terminology, selecting the appropriate food safety standard, and what it means to be "audit ready". It also provides definitions and objectives of food safety audits. Key points made include criticisms of some auditing practices, the roles and limitations of audits, and information on standards organizations like ISO, GFSI initiatives, and the purpose of establishing the GFSI.
This document summarizes the key aspects of food traceability from compliance to opportunity. Traceability has become a regulatory requirement in both the EU and US to identify unsafe food and enable recalls. It allows food to be tracked from farm to fork through all stages of production, processing, and distribution. While traceability ensures compliance, it can also provide brand protection and market access opportunities when customers demand transparency in supply chains. Technologies continue to advance traceability capabilities from paper-based systems to electronic tracking using barcodes, RFID, and analytical techniques. Effective traceability gives organizations supply chain visibility to communicate their practices and story to consumers.
This document discusses key differences between generic and cold chain supply quality management systems. A Middle Eastern cold chain is more expensive due to temperature extremes and immature regulations. Qualification and validation are often misunderstood, with qualification establishing a process can meet standards through testing, while validation tests a process under controlled conditions. For manufacturing, processes can be validated, but distribution is variable so can only be qualified. Extending quality oversight beyond manufacturing, understanding regulators, having product knowledge, and documenting every cold chain link are critical for quality assurance. Tools like CCQI, HACCP, and inventory management systems can help optimize quality strategies for specific cold chain challenges.
This document proposes strengthening regulations for the recycling of waste cooking oils (WCO) generated by restaurants and food factories in Hong Kong. It suggests introducing licenses for WCO collection, disposal, and import/export. Operators without licenses would face fines or imprisonment. It also proposes that restaurants and food factories be required to hand over their WCO only to licensed collectors and keep transaction records. The Environmental Protection Department will implement a voluntary registration system for WCO operators and develop best practices to facilitate proper handling and recycling of WCO.
The Japanese Ministry of Health, Labor and Welfare revised the Drinking Water Quality Standards in 2003. Key changes included expanding the number of regulated items from 46 to 50, adding items like E. coli and aluminum, and introducing a rolling revision system to continuously improve standards. A new framework was established with Drinking Water Quality Standards, Complementary items including 101 pesticides, and Items for Further Study. Water suppliers must now prepare Water Quality Analysis Plans outlining their testing procedures.
1. The document discusses food regulation in Indonesia, including standards and guidelines for food safety.
2. It outlines Indonesia's system for regulating food producers, industries, and consumers to ensure better quality and safer foods. Key government agencies establish laws, regulations, standards, and oversee monitoring of the food system.
3. Standards address issues across the food supply chain from agricultural production to processing and marketing. This includes good practices for farming, handling, manufacturing, distribution and more to prevent contamination and improve food quality and safety.
The document discusses current regulatory perspectives on genetically modified (GM) food in Indonesia. It provides an overview of the global situation and regulations regarding GM foods. It then outlines Indonesia's policies, including that GM foods must undergo pre-market biosafety assessment and be labeled if they contain GM materials above a certain threshold. The key laws and regulations governing GM foods in Indonesia are also summarized. [END SUMMARY]
The document provides information about a workshop on veterinary products in Asian countries held in Korea in 2010. It includes an introduction to Pakistan, describing its geography, population, provinces, climate and economy. It also discusses the Ministry of Health in Pakistan and the Drug Control Organization, which regulates drug manufacture, registration, pricing, import and export. The final sections describe the drug registration process and forms used in Pakistan.
This document discusses India's animal quarantine services and their objectives of preventing the introduction of exotic livestock diseases. It outlines the quarantine stations located across India and their economic importance in saving money through disease prevention and increasing exports. Regulations regarding livestock imports and exports are discussed, highlighting the need for mandatory animal quarantine clearance. Proper technical export certification is emphasized as important for increasing trade and meeting international standards.
This document discusses improving the effectiveness of online advertising. It provides data on typical rates of ads hitting their intended target audience and being viewable. It then presents a case study of how ConAgra Foods worked with partners to optimize campaigns for higher in-target and viewable delivery rates, which improved branding impact. Key recommendations included integrating viewability reporting, aligning goals with media sellers, and optimizing for audience and viewability. Top burning questions from advertisers are also listed around these topics.
More from Asian Food Regulation Information Service (20)
A Guide to AI for Smarter Nonprofits - Dr. Cori Faklaris, UNC CharlotteCori Faklaris
Working with data is a challenge for many organizations. Nonprofits in particular may need to collect and analyze sensitive, incomplete, and/or biased historical data about people. In this talk, Dr. Cori Faklaris of UNC Charlotte provides an overview of current AI capabilities and weaknesses to consider when integrating current AI technologies into the data workflow. The talk is organized around three takeaways: (1) For better or sometimes worse, AI provides you with “infinite interns.” (2) Give people permission & guardrails to learn what works with these “interns” and what doesn’t. (3) Create a roadmap for adding in more AI to assist nonprofit work, along with strategies for bias mitigation.
Combined Illegal, Unregulated and Unreported (IUU) Vessel List.Christina Parmionova
The best available, up-to-date information on all fishing and related vessels that appear on the illegal, unregulated, and unreported (IUU) fishing vessel lists published by Regional Fisheries Management Organisations (RFMOs) and related organisations. The aim of the site is to improve the effectiveness of the original IUU lists as a tool for a wide variety of stakeholders to better understand and combat illegal fishing and broader fisheries crime.
To date, the following regional organisations maintain or share lists of vessels that have been found to carry out or support IUU fishing within their own or adjacent convention areas and/or species of competence:
Commission for the Conservation of Antarctic Marine Living Resources (CCAMLR)
Commission for the Conservation of Southern Bluefin Tuna (CCSBT)
General Fisheries Commission for the Mediterranean (GFCM)
Inter-American Tropical Tuna Commission (IATTC)
International Commission for the Conservation of Atlantic Tunas (ICCAT)
Indian Ocean Tuna Commission (IOTC)
Northwest Atlantic Fisheries Organisation (NAFO)
North East Atlantic Fisheries Commission (NEAFC)
North Pacific Fisheries Commission (NPFC)
South East Atlantic Fisheries Organisation (SEAFO)
South Pacific Regional Fisheries Management Organisation (SPRFMO)
Southern Indian Ocean Fisheries Agreement (SIOFA)
Western and Central Pacific Fisheries Commission (WCPFC)
The Combined IUU Fishing Vessel List merges all these sources into one list that provides a single reference point to identify whether a vessel is currently IUU listed. Vessels that have been IUU listed in the past and subsequently delisted (for example because of a change in ownership, or because the vessel is no longer in service) are also retained on the site, so that the site contains a full historic record of IUU listed fishing vessels.
Unlike the IUU lists published on individual RFMO websites, which may update vessel details infrequently or not at all, the Combined IUU Fishing Vessel List is kept up to date with the best available information regarding changes to vessel identity, flag state, ownership, location, and operations.
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
RFP for Reno's Community Assistance CenterThis Is Reno
Property appraisals completed in May for downtown Reno’s Community Assistance and Triage Centers (CAC) reveal that repairing the buildings to bring them back into service would cost an estimated $10.1 million—nearly four times the amount previously reported by city staff.
karnataka housing board schemes . all schemesnarinav14
The Karnataka government, along with the central government’s Pradhan Mantri Awas Yojana (PMAY), offers various housing schemes to cater to the diverse needs of citizens across the state. This article provides a comprehensive overview of the major housing schemes available in the Karnataka housing board for both urban and rural areas in 2024.
1. CFDA
CCFDIE
1
Brief Introduction of
China Food and Drug Administration
Chang Yongheng
China Center for Food and Drug International Exchange
China Food and Drug Administration
April 9, 2014
2. CFDA
CCFDIE
April 9, 2014 2
Content
Background
Focus of Reform
CFDA Internal Offices and Main Responsibilities
Division of Regulatory Authority among Ministries
Division of Regulatory Authority between CFDA and
local FDA
5. CFDA
CCFDIE
5
Focus of Reform
2. Streamline and strengthen responsibility of
different Ministries, co-operation to ensure
food safety.
3. Establish and improve grass-roots food and
drug management system.
April 9, 2014
7. CFDA
CCFDIE
7
Focus of Reform
5. Strengthen and elevate food and drug
regulatory capacity.
6. Transform and optimize government
functions.
CFDA cancels 4 administrative licensing items,
delegate 5 items and integrate 5 items.
April 9, 2014
8. CFDA
CCFDIE
State Council
8
CFDA Internal Offices and Main
Responsibilities
CFDA has administrative staffing of 345
17 Internal Offices
Ministerial-level Agency
… …
SAWS
SAIC
AQSIQ
CFDA
April 9, 2014
9. CFDA
CCFDIE
9
CFDA Internal Offices and Main
Responsibilities
CFDA Main Responsibilities
1. Draft and formulate laws, regulations and normative documents;
2. Formulate the regulations on food administrative licensing and
supervise its implementation;
3. Organize the formulation and publication of drug and medical
device standards and classification system, and supervise their
implementation;
4. Formulate the investigation and enforcement system and
organize its implementation;
5. Establish food and drug emergency response system;
6. Formulate science and technology development plans for food
and drug safety, and organize its implementation.
April 9, 2014
10. CFDA
CCFDIE
10
CFDA Internal Offices and Main
Responsibilities
7 Departments
of Administration
General
Office
Comprehensive
Department
Department
of Media
and Publicity
Department
of Legal
Affairs
Department
of Human
Resources
Department of
International
Cooperation
(Office of
Hong Kong,
Macao and
Taiwan Affairs)
Department
of Planning
& Finance
April 9, 2014
11. CFDA
CCFDIE
11
CFDA Internal Offices and Main
Responsibilities
10 Departments
of Operation
3 departments
of food
2 departments
of drug
&cosmetics
2 departments
of medical
device
3 other
departments
April 9, 2014
12. CFDA
CCFDIE
12
CFDA Internal Offices and Main
Responsibilities
3 Departments
of Food
Department of
Food Safety
Supervision I
Department of
Food Safety
Supervision II
Department of
Food Safety
Supervision III
April 9, 2014
13. CFDA
CCFDIE
13
CFDA Internal Offices and Main
Responsibilities
2 Departments
of Drug
& Cosmetics
Dept. of
Drug and Cosmetics
Registration
Dept.
of Drug and
Cosmetics
Supervision
April 9, 2014
14. CFDA
CCFDIE
14
CFDA Internal Offices and Main
Responsibilities
2 Departments
of Medical
Device
Dept. of
Medical Device
Registration
Dept. of
Medical Device
Supervision
April 9, 2014
15. CFDA
CCFDIE
15
CFDA Internal Offices and Main
Responsibilities
3 Other
Departments
Dept.
of Science and
Technology
Bureau of
Investigation
and Enforcement
Dept.
of Emergency
Management
April 9, 2014
16. CFDA
CCFDIE
16
Main Affiliated Institutions and Responsibilities
National Committee on the Assessment of
the Protected Traditional Chinese Medicinal
Products (Center for Health Food Evaluation))
Center for Medical Device Evaluation
Center for Complaints and Report
National Institutes for Food and Drug Control
(Center for Medical Device Standardization
Administration)
Chinese Pharmacopoeia Commission
Center for Drug Evaluation
投诉举报中心
National statutory Institutions and the highest
technical arbitration body for drugs and biological products
Organize Chinese Pharmacopoei compilation, formulate
and revise national Pharmaceutical standards as
statutory national drug standard management agency
Undertake national TCM protection and
technical review of health food, cosmetics approval
Responsible for technical review of drug registration appli-
cations as CFDA Drug Registration technical review Agency
Responsible for technical review of import medical
devices and domestic Class Ⅲ medical Devices
Accept complaints for illegal activities in medicines, medical
devices, health food and cosmetics in development,production,
distribution, use and catering food service
Responsible for conducting pharmaceutical / medical device
Adverse Reactions / events monitoring at home and abroad
Center for Drug Reevaluation (National
Center for ADR Monitoring)
April 9, 2014
China Center for Food and Drug
International Exchange (CCFDIE)
Responsible for international exchange and cooperation
activities with international organizations or the industry
18. CFDA
CCFDIE
18
Division of Regulatory Authority
among Ministries
II. Administrative convergence mechanism
gradually established.
Food safety track system
CFDA Ministry of Agriculture
Import and export food safety information rapid
notification system
CFDA AQSIQ
Food safety risk assessment and standard
coordination system
CFDA NHFPC
April 9, 2014
19. CFDA
CCFDIE Division of Regulatory Authority
among Ministries
III. Judicial linkage mechanism gradually
improved.
CFDA Ministry of Public
Security
April 9, 2014
20. CFDA
CCFDIE
20
Division of Regulatory Authority
between CFDA and local FDA
Goal
upper and lower linkage
joint push pull
smooth operation
overall improvement
April 9, 2014
21. CFDA
CCFDIE
21
Division of Regulatory Authority
between CFDA and local FDA
Drug regulation
CFDA is responsible for review and approval of new
drugs and generic drug registration.
Local FDA is responsible for daily supervision and
inspection of listed companies within areas under its
jurisdiction.
April 9, 2014
22. CFDA
CCFDIE
22
Division of Regulatory Authority
between CFDA and local FDA
Medical Device Regulation
CFDA is responsible for review and approval of
Class Ⅲ and import medical device registration.
Local FDA is responsible for ClassⅠand Ⅱmedical
device registration, as well as daily supervision and
inspection of listed companies within areas under its
jurisdiction.
April 9, 2014
23. CFDA
CCFDIE
23
Division of Regulatory Authority
between CFDA and local FDA
Food safety supervision
CFDA is responsible for formulating policies, annual
plans and unified information publication system.
Local FDA is responsible for administrative
licensings , daily supervision and inspection of listed
companies within areas under its jurisdiction.
April 9, 2014